FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955524650> ?p ?o ?g. }

• W2955524650 endingPage "e028147" @default.
• W2955524650 startingPage "e028147" @default.
• W2955524650 abstract "Introduction Neoadjuvant chemotherapy (NACT) is considered the current standard for locally advanced gallbladder cancer (GBC). There is no consensus on the optimal neoadjuvant approach. A pilot study from our institution has shown improved overall survival (OS) and progression-free survival (PFS) with neoadjuvant chemoradiation (NACRT). The present randomised phase III trial is designed to compare NACRT with NACT alone and will test the superiority of chemoradiation in terms of tumour downstaging and improvement in OS. Methods and analysis Patients with biopsy-proven locally advanced GBC (T3–4) with predefined clinical–radiological features will be randomised to the gemcitabine-based chemotherapy-alone arm or the chemoradiation arm. Patients with resectable disease or with distant metastases will be excluded. The primary end point of the study is to compare OS between the two arms. The secondary end point was to compare PFS, R0 resection rates, acute and late toxicity, postoperative complications and quality of life between the two study arms. The trial is designed to detect an improvement in median OS by 5.5 months in the study arm (11 months in the control group, HR of 0.7) with 80.0% power at a 0.05 significance level. The resultant sample size to achieve this aim is 314 (157 in each arm) over a duration of 5 years with a 10% attrition rate. Ethics and dissemination The institutional ethics committee has approved this trial and will be routinely monitoring the trial at frequent intervals. The results of the study will be disseminated via peer-reviewed scientific journals, conference presentations and submission to regulatory authorities. Registration The trial is registered with Clinical Trials Registry India (CTRI/2016/08/007199) and ClinicalTrials.gov ( NCT02867865 ). This trial aims to assess the superiority of NACRT over NACT in locally advanced GBCs in terms of improvement in OS. The results of this study will define the optimal neoadjuvant approach in locally advanced GBC. Trial registration number NCT02867865 ; Pre-results." @default.
• W2955524650 created "2019-07-12" @default.
• W2955524650 creator A5001774710 @default.
• W2955524650 creator A5027721017 @default.
• W2955524650 creator A5033979776 @default.
• W2955524650 creator A5041539193 @default.
• W2955524650 creator A5041554293 @default.
• W2955524650 creator A5046703388 @default.
• W2955524650 creator A5050313092 @default.
• W2955524650 creator A5056573159 @default.
• W2955524650 creator A5067203437 @default.
• W2955524650 creator A5071089813 @default.
• W2955524650 creator A5081409635 @default.
• W2955524650 date "2019-06-01" @default.
• W2955524650 modified "2023-09-30" @default.
• W2955524650 title "A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol" @default.
• W2955524650 cites W1975601891 @default.
• W2955524650 cites W1988304505 @default.
• W2955524650 cites W2010851248 @default.
• W2955524650 cites W2012178169 @default.
• W2955524650 cites W2019607817 @default.
• W2955524650 cites W2022166870 @default.
• W2955524650 cites W2042251496 @default.
• W2955524650 cites W2085113277 @default.
• W2955524650 cites W2087429563 @default.
• W2955524650 cites W2096998881 @default.
• W2955524650 cites W2114139737 @default.
• W2955524650 cites W2115261608 @default.
• W2955524650 cites W2161286972 @default.
• W2955524650 cites W2168563465 @default.
• W2955524650 cites W2332605220 @default.
• W2955524650 cites W2340940846 @default.
• W2955524650 cites W2758922267 @default.
• W2955524650 cites W2801912900 @default.
• W2955524650 cites W99036699 @default.
• W2955524650 doi "https://doi.org/10.1136/bmjopen-2018-028147" @default.
• W2955524650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6609079" @default.
• W2955524650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31253621" @default.
• W2955524650 hasPublicationYear "2019" @default.
• W2955524650 type Work @default.
• W2955524650 sameAs 2955524650 @default.
• W2955524650 citedByCount "11" @default.
• W2955524650 countsByYear W29555246502020 @default.
• W2955524650 countsByYear W29555246502021 @default.
• W2955524650 countsByYear W29555246502022 @default.
• W2955524650 countsByYear W29555246502023 @default.
• W2955524650 crossrefType "journal-article" @default.
• W2955524650 hasAuthorship W2955524650A5001774710 @default.
• W2955524650 hasAuthorship W2955524650A5027721017 @default.
• W2955524650 hasAuthorship W2955524650A5033979776 @default.
• W2955524650 hasAuthorship W2955524650A5041539193 @default.
• W2955524650 hasAuthorship W2955524650A5041554293 @default.
• W2955524650 hasAuthorship W2955524650A5046703388 @default.
• W2955524650 hasAuthorship W2955524650A5050313092 @default.
• W2955524650 hasAuthorship W2955524650A5056573159 @default.
• W2955524650 hasAuthorship W2955524650A5067203437 @default.
• W2955524650 hasAuthorship W2955524650A5071089813 @default.
• W2955524650 hasAuthorship W2955524650A5081409635 @default.
• W2955524650 hasBestOaLocation W29555246501 @default.
• W2955524650 hasConcept C121608353 @default.
• W2955524650 hasConcept C126322002 @default.
• W2955524650 hasConcept C141071460 @default.
• W2955524650 hasConcept C143998085 @default.
• W2955524650 hasConcept C168563851 @default.
• W2955524650 hasConcept C203092338 @default.
• W2955524650 hasConcept C2776534502 @default.
• W2955524650 hasConcept C2776694085 @default.
• W2955524650 hasConcept C2778292576 @default.
• W2955524650 hasConcept C2778424827 @default.
• W2955524650 hasConcept C2780258809 @default.
• W2955524650 hasConcept C31174226 @default.
• W2955524650 hasConcept C509974204 @default.
• W2955524650 hasConcept C530470458 @default.
• W2955524650 hasConcept C535046627 @default.
• W2955524650 hasConcept C71924100 @default.
• W2955524650 hasConceptScore W2955524650C121608353 @default.
• W2955524650 hasConceptScore W2955524650C126322002 @default.
• W2955524650 hasConceptScore W2955524650C141071460 @default.
• W2955524650 hasConceptScore W2955524650C143998085 @default.
• W2955524650 hasConceptScore W2955524650C168563851 @default.
• W2955524650 hasConceptScore W2955524650C203092338 @default.
• W2955524650 hasConceptScore W2955524650C2776534502 @default.
• W2955524650 hasConceptScore W2955524650C2776694085 @default.
• W2955524650 hasConceptScore W2955524650C2778292576 @default.
• W2955524650 hasConceptScore W2955524650C2778424827 @default.
• W2955524650 hasConceptScore W2955524650C2780258809 @default.
• W2955524650 hasConceptScore W2955524650C31174226 @default.
• W2955524650 hasConceptScore W2955524650C509974204 @default.
• W2955524650 hasConceptScore W2955524650C530470458 @default.
• W2955524650 hasConceptScore W2955524650C535046627 @default.
• W2955524650 hasConceptScore W2955524650C71924100 @default.
• W2955524650 hasIssue "6" @default.
• W2955524650 hasLocation W29555246501 @default.
• W2955524650 hasLocation W29555246502 @default.
• W2955524650 hasLocation W29555246503 @default.
• W2955524650 hasLocation W29555246504 @default.
• W2955524650 hasOpenAccess W2955524650 @default.
• W2955524650 hasPrimaryLocation W29555246501 @default.

• next